Purple Biotech ADR earnings missed, revenue was in line with estimates

  • Investing.com
Purple Biotech ADR earnings missed, revenue was in line with estimates

Investing.com - Purple Biotech ADR (NASDAQ: PPBT ) reported third quarter EPS of $-0.230, worse than the analyst estimate of $-0.227. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.

Purple Biotech ADR's stock price closed at $1.000. It is down -14.530% in the last 3 months and down -50.130% in the last 12 months.

Purple Biotech ADR saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Purple Biotech ADR's stock price’s past reactions to earnings here.

According to InvestingPro, Purple Biotech ADR's Financial Health score is "fair performance".

Check out Purple Biotech ADR's recent earnings performance , and Purple Biotech ADR's financials here.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100